BioStock: NeuroVive presents new strategy for NeuroSTAT

In October, NeuroVive introduced a new strategy for the company – instead of spreading its resources across four indication areas, they chose to focus their work on primary mitochondrial diseases. Of the company’s other three projects, NeuroSTAT against traumatic brain injury (TBI) is the most advanced, and NeuroVive now plans to transfer the rights to develop and commercialise NeuroSTAT to a new company in the United States. CEO Erik Kinnman told BioStock more about this move.

Read the full article and interview at

This is a press release from BioStock - Connecting Innovation & Capital.

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).


Quick facts

BioStock: NeuroVive presents new strategy for NeuroSTAT
Tweet this